Filing Flows › Health Care › Sunshine Biopharma (SBFM)
Sunshine Biopharma (SBFM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Sunshine Biopharma (SBFM) Q2 2026 earnings results →
Q2 2026 Revenue down 2% year over year to $9.3M · 17¢ of every $1 of revenue lost · operating margin -17.4%
Sunshine Biopharma made $9.3M in Q2 2026 (-2% Y/Y). Operating margin -17.4%, net loss $1.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.3M in Q2 2026, down 2% year over year and up 15% from the previous quarter.
Gross margin was 26.2%, down 10.2 points from Q2 2025. Operating costs exceeded revenue by $1.6M, an operating margin of -17.4%. Operating expenses fell 26% while revenue fell 2%. The quarter ended with a net loss of $1.6M, wider than the previous quarter's $1.2M loss.
Operating cash flow was −$918K. Non-cash charges added back $78K of depreciation and amortization. Working capital and other items added $568K. Capital expenditures of $7K exceeded it, leaving free cash flow of −$925K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $9.3M | -2% | -17.4% | −$1.6M | −$918K |
| Q1 2026 | 10-Q | May 13, 2026 | $8.1M | -9% | -17.3% | −$1.2M | −$2.1M |
| Q4 2025 | 10-K | Apr 3, 2026 | $8.6M | -11% | -20.9% | −$2.1M | −$1.6M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $9.4M | +12% | -11.5% | −$884K | −$747K |
| Q2 2025 | 10-Q | Aug 12, 2025 | $9.4M | +1% | -21.8% | −$1.8M | −$1.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $8.9M | +18% | -14.6% | −$1.2M | −$1.7M |
| Q4 2024 | 10-K | Apr 1, 2025 | $9.6M | +25% | -21.2% | −$2.2M | −$3.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Sunshine Biopharma
We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc. (“Nora Pharma”), a Canadian corporation, through which we currently have 71 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian corporation which develops and sells OTC supplements. In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.
In its own words, from its 10-K, filed Apr 3, 2026.
Sunshine Biopharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +7%. Operating margin: -17.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SBFM Sunshine Biopharma | Q2 2026 | $9.3M | -2% | -17.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Sunshine Biopharma 10-Q on SEC EDGAR · CIK 1402328 · Pharmaceutical Preparations
More on SBFM
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results